Abstract:Abstracts Objectives Recent international trade agreements require member countries a prolonged statutory exclusivity for biologics, and domestic legislation guarantees various forms of exclusivity for specific drugs, indications, or studies. This study notes prolonged exclusivity provisions for biologics in the United States and international trade agreements. We aim to review various exclusivity systems, including chemical entities, in selected high-income countries and to suggest implications for establishing the system specifically relevant for biologics in low- and middle-income countries. Methods We conducted a review of a comprehensive range of literature to develop the framework. Then, a comparative legal analysis was conducted to analyze the deviations among the systems in the European Union, Canada, South Korea, Australia, and the United States. Results There is constructive ambiguity in international trade agreements, specifically for provisions regarding biologics. Furthermore, the selected countries operate different statutory exclusivity systems in terms of eligibility for statutory exclusivity, specific measures for exclusivity, and other elements of exclusivity. In addition, market exclusivity, which is distinguished from data exclusivity, is not available in Korea and Australia. There are also various forms of statutory exclusivity for specific drugs, indications, or studies requested by the marketing authority. Conclusions Given constructive ambiguities in international agreements and variations in the manner of implementations of the systems in selected countries, statutory exclusivity for biologics could be established with cautions to mediate the harms. In this study, we suggest several solutions and alternatives for low- and middle-income countries.

Setting Method Study of Data Protection Period for Biologics——Based on the Comparative Analysis of American and Japanese Methods

Analysis of the Legislative Evolution and Causes of Biologics Data Protection System in the United States

Comparative Study on Pharmaceutical Data Protection System of China and Japan

Data protection provisions for biologics in TPP and policy orientation in China

Analysis of the Regulatory Policies Progress of Biosimilars in Foreign Countries and Its Enlightenment to China

Study on the positive effects of data protection system on the availability of innovative drug--based on a comparative analysis of keppra marketing between China and America

Study on Status and Countermeasures about Biosimilars in China

Policy selection of regulatory data protection under the background of drug innovation strategy in China

The Discussion on strategy improving the safety in human bioequivalence study

Comparison and Analysis of the Health Products Supervisions in China,Japan,USA and EU

Comparative Study of GMP Used in China and Japan

Research on the Safety Monitoring Effects of Pediatric Drug Data Protection Regime in the US

Comparison of the policy of controlling fees of medicare drugs in China and the United States from the perspective of medical resource balance

Balancing Industry And Drug Policy Objectives In The Pharmaceutical Sector: The Case Of China

Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States

Analysis of Biopharmaceutical Innovation Investment in China and Its Policy Causes——On the Basis of the Status Quo of Innovation Investment in United States, Europe and China by Empirical Evaluation

International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market

Comparative Analysis on the Practice of Drug Risk Management in China

A Risk-Based Approach to Setting Acceptance Criteria for Pharmaceutical Process Comparability

Comparative Analysis of the Industry Status & Trend between Biosimilars and Biobetters

Performance of Registration Regulation Policies on Biosimilars in Japan and Its Enlightenment